WallStSmart
SNY

Sanofi ADR

NASDAQ: SNY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$46.58
+1.19% today

Updated 2026-04-30

Market cap
$112.08B
P/E ratio
20.16
P/S ratio
2.40x
EPS (TTM)
$2.32
Dividend yield
8.67%
52W range
$43 – $53
Volume
3.5M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Sanofi ADR (SNY) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$46.58
Consensus
$58.00
+24.52%
2030 Target
$325.65
+599.12%
DCF
$61.95
+24.08% MoS
25 analysts:
1 Buy3 Hold0 Sell

Management guidance

No specific CEO revenue targets disclosed in available documents. Latest analyst consensus projects FY2026 revenue of €48.52B ($52.4B USD equiv.) and FY2027 of €51.26B ($55.4B USD equiv.), representing 3.86% and 5.64% growth respectively. Management has not provided 2028-2030 explicit guidance.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$541.16
$65.9B Rev × 20x P/S
Base case (2030)
$325.65
$65.9B Rev × 12x P/S
Bear case (2030)
$215.51
$65.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$41.6B$44.3B$46.7B$52.4B$55.4B$58.8B$62.3B$65.9B
Revenue growth—6.4%5.5%3.9%5.6%6.1%6.0%5.8%
EPS$5.77$4.12$5.15$8.48$8.94$9.45$9.98$10.54
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$258.61$272.97$287.34$306.50$325.65

Catalysts & risks

Growth catalysts
+ Dupixent (dupilumab) approvals in new indications (allergic fungal rhinosinusitis, pediatric urticaria) driving revenue expansion
+ Rezurock (belumosudil) EU conditional approval for chronic GVHD with €490M 2025 sales; further growth expected 2026+
+ Pipeline advancement: amlitelimab Phase 3 completion for atopic dermatitis, venglustat Breakthrough Therapy designation for Gaucher disease Type 3, mRNA CAR-T platform development
+ Strategic acquisitions/partnerships: $180M upfront for Kali Therapeutics KT501 autoimmune drug, $1.5B deal with Sino Biopharmaceuticals, AI collaborations with Earendil Labs
Key risks
- Dupixent succession drug (amlitelimab) shows mixed eczema data with safety concerns; expectations for Dupixent successor declining
- Competitive pressure from Apogee Therapeutics' zumilokibart (anti-IL-13) in atopic dermatitis with superior dosing profile; peak sales forecasts doubled to $5.2B
- R&D execution risk: Multiple analyst downgrades (UBS, Guggenheim, JP Morgan, BofA) citing R&D track record concerns; pipeline hurdles remain elevated
- Dupixent patent cliff approaching; revenue concentration risk on single blockbuster
- Recent analyst sentiment shift: 3 downgrades to Hold in past 4 months despite Morgan Stanley upgrade; consensus deteriorating

Methodology

Sanofi ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 25 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.